Health
LegoChem Biosciences and Iksuda Therapeutics expand License Agreement for development of antibody-drug conjugates – News-Medical.net
Iksuda Therapeutics today announced that it has expanded its research collaboration and License Agreement with LegoChem Biosciences,…
Iksuda Therapeutics, the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, today announced that it has expanded its research collaboration and License Agreement with LegoChem Biosciences, Inc. (“LCB”) to explore…
Continue Reading
-
General17 hours agoAbattoir worker in serious condition after workplace accident in Echuca
-
General22 hours ago‘Sovereign citizens’ sentenced to prison term in Western Australia for defiance of court order
-
General17 hours agoWoman who reported NSW MP Gareth Ward’s alleged sex crimes cross-examined
-
Noosa News7 hours agoFull house as Minister shares vision for Sunshine Coast transport